Int J Hematol. 1991 Oct;54(5):371-5.

The effects of subcutaneous deferoxamine administration on renal function in thalassemia major.

Koren G, Kochavi-Atiya Y, Bentur Y, Olivieri NF.

Source

Division of Clinical Pharmacology, Hospital for Sick Children, Toronto, Canada.

Abstract

To assess the effects of deferoxamine (DFO) on the kidneys, we studied 27 patients with thalassemia major on chronic subcutaneous (s.c.) DFO therapy. In 41% of the patients glomerular filtration rate (GFR) values were above the normal range. In a previous study similar findings were reported for thalassemia patients who did not receive DFO. The subcutaneous administration of DFO was associated with a clinically significant decrease in GFR in 40% of the patients and in a mild decrease in another 40%. In all cases of severe decreases in GFR, it tended to return to baseline values upon discontinuation of DFO. There was a significant increase in urine volume during DFO therapy. These changes are consistent with our previous observation in humans and dogs receiving high dose i.v. DFO, albeit milder.

PMID:: 1756248; [PubMed - indexed for MEDLINE]

Publication Types, MeSH Terms, Substances

Publication Types

Research Support, Non-U.S. Gov't

MeSH Terms

Substances

Deferoxamine

LinkOut - more resources

Other Literature Sources

Labome Researcher Resource - ExactAntigen/Labome

Medical

Molecular Biology Databases

DESFERRIOXAMINE - HSDB

Libraries

LinkOut Holdings

Supplemental Content

Save items

Related citations in PubMed

Toxic effects of high-dose deferoxamine treatment in patients with iron overload: an electrophysiological study of cerebral and visual function. [Haematologica. 1991]
Toxic effects of high-dose deferoxamine treatment in patients with iron overload: an electrophysiological study of cerebral and visual function.
Marciani MG, Cianciulli P, Stefani N, Stefanini F, Peroni L, Sabbadini M, Maschio M, Trua G, Papa G. Haematologica. 1991 Mar-Apr; 76(2):131-4.
Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta-thalassemia. [Clin Ther. 2007]
Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta-thalassemia.
Cappellini MD, Bejaoui M, Agaoglu L, Porter J, Coates T, Jeng M, Lai ME, Mangiagli A, Strauss G, Girot R, et al. Clin Ther. 2007 May; 29(5):909-17.
High-dose intravenous desferrioxamine (DFO) delivery in four thalassemic patients allergic to subcutaneous DFO administration. [Am J Hematol. 1996]
High-dose intravenous desferrioxamine (DFO) delivery in four thalassemic patients allergic to subcutaneous DFO administration.
Lombardo T, Ferro G, Frontini V, Percolla S. Am J Hematol. 1996 Jan; 51(1):90-2.
Review Recent insights into interactions of deferoxamine with cellular and plasma iron pools: Implications for clinical use. [Ann N Y Acad Sci. 2005]
Review Recent insights into interactions of deferoxamine with cellular and plasma iron pools: Implications for clinical use.
Porter JB, Rafique R, Srichairatanakool S, Davis BA, Shah FT, Hair T, Evans P. Ann N Y Acad Sci. 2005; 1054:155-68.
Review Chelation therapy in beta-thalassemia: the benefits and limitations of desferrioxamine. [Semin Hematol. 1995]
Review Chelation therapy in beta-thalassemia: the benefits and limitations of desferrioxamine.
Giardina PJ, Grady RW. Semin Hematol. 1995 Oct; 32(4):304-12.

See reviews... See all...

Cited by 1 PubMed Central article

Renal functions in pediatric patients with beta-thalassemia major: relation to chelation therapy: original prospective study. [Ital J Pediatr. 2010]
Renal functions in pediatric patients with beta-thalassemia major: relation to chelation therapy: original prospective study.
Hamed EA, ElMelegy NT. Ital J Pediatr. 2010 May 25; 36:39. Epub 2010 May 25.

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Compound (MeSH Keyword)
PubChem chemical compound records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

The effects of subcutaneous deferoxamine administration on renal function in tha...
The effects of subcutaneous deferoxamine administration on renal function in thalassemia major.
Int J Hematol. 1991 Oct ;54(5):371-5.

PubMed
Growth of infants with IgE-mediated cow's milk allergy fed different formulas in...
Growth of infants with IgE-mediated cow's milk allergy fed different formulas in the complementary feeding period.
Pediatr Allergy Immunol. 2007 Nov ;18(7):599-606. Epub 2007 Jun 11 .

PubMed
The placental transfer of calcium.
The placental transfer of calcium.
J Dev Physiol. 1991 May ;15(5):253-7.

PubMed
Cystatin C and beta2-microglobulin: markers of glomerular filtration in critical...
Cystatin C and beta2-microglobulin: markers of glomerular filtration in critically ill children.
Crit Care. 2007 ;11(3):R59.

PubMed
Gestational diabetes mellitus. A survey of perinatal complications in the 1980s.
Gestational diabetes mellitus. A survey of perinatal complications in the 1980s.
Diabetes. 1991 Dec ;40 Suppl 2:74-8.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to: